Every material Form 8-K Supernus Pharmaceuticals filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Supernus Pharmaceuticals completed a merger on November 2, 2026, and asked Nasdaq to suspend trading in its common stock before the market opened that day. The company will be removed from Nasdaq and will stop being a publicly listed stock, so shares will no longer trade on any national securities exchange.
Merger consummated November 2, 2026; trading in Supernus common stock suspended before market open that day
Company requested Nasdaq file a Form 25 to delist the stock and deregister it under Section 12(b)
After Form 25 takes effect, company intends to file Form 15 to deregister under Section 12(g) and suspend SEC reporting obligations
Supernus Pharmaceuticals has completed its merger with Indivior Pharmaceuticals, forming a combined entity operating as Supernus, Inc. Under the terms of the agreement, Supernus stockholders received 1.5401 shares of Indivior common stock for each share owned, resulting in former Indivior stockholders owning approximately 56.5% and former Supernus stockholders owning approximately 43.5% of the combined company. The company also entered into a $650 million senior secured term loan facility to help fund a $1.0 billion special cash dividend to legacy Indivior stockholders.
The merger was completed on November 2, 2026, combining Supernus Pharmaceuticals and Indivior Pharmaceuticals into Supernus, Inc.
Supernus stockholders received 1.5401 shares of Indivior common stock for each share of Supernus common stock owned.
The combined company secured a $650 million term loan facility with Citibank, N.A. to help finance a $1.0 billion aggregate special cash dividend to legacy Indivior stockholders.
Former Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.
Supernus reported third-quarter 2026 total revenues of $226.8 million, up 18% from a year earlier, and net earnings of $20.9 million, or $0.35 per diluted share, compared with a net loss of $45.1 million a year earlier. The company raised its full-year 2026 total revenue and GAAP operating earnings guidance, but the guidance will no longer apply if the Indivior merger closes as expected on November 2, 2026.
Q3 2026 net earnings were $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or $0.80 per share, in Q3 2025.
Total revenues were $226.8 million, up from $192.1 million; ONAPGO net sales rose to $17.1 million from $6.8 million.
2026 total revenue guidance was raised to $875 million to $900 million from $860 million to $890 million.
The Indivior merger is expected to close November 2, 2026; Supernus common stock is expected to trade under SUPN on November 3, 2026.
Supernus Pharmaceuticals terminated its uncommitted UBS revolving credit line on October 20, 2026, in connection with its planned business combination with Indivior Pharmaceuticals and a new senior secured credit facility for the combined company. The company reported no outstanding borrowings and no early termination penalties, so the termination itself has no direct financial cost disclosed in the filing.
Terminated UBS Credit Line Agreement dated February 8, 2023, with UBS Bank USA on October 20, 2026
No advances, letters of credit or other borrowings were outstanding at termination
No early termination penalties were incurred; the Bank's security interests in the collateral were released
Termination tied to the pending combination with Indivior Pharmaceuticals under a merger agreement dated August 1, 2026
Supernus said the FDA recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for motor fluctuations in adults with advanced Parkinson's disease, with the exclusivity period starting on the February 3, 2025 approval date. The company also submitted a supplemental New Drug Application for a second supplier of ONAPGO and continues to expect potential FDA approval of that supplier by mid-year 2027. The filing gives no financial figures, but the exclusivity period is a regulatory protection for the product.
FDA recognized seven years of orphan-drug exclusive approval for ONAPGO, with the period starting February 3, 2025.
ONAPGO is described as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson's disease.
Supernus submitted an sNDA for a second supplier of ONAPGO and expects potential FDA approval by mid-year 2027.
Supernus Pharmaceuticals said it will report its third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026. The filing announces the timing and call details only and includes no financial results, so it gives shareholders no new performance figures yet.
Third quarter 2026 results will be released after the market closes on Thursday, October 29, 2026.
A conference call and webcast hosted by CEO Jack Khattar and CFO Tim Dec is set for 4:30 p.m. ET on October 29, 2026.
The filing contains no revenue, profit, or guidance figures.
Supernus reported second-quarter 2026 total revenues of $219.1 million, up 32% from a year earlier, and raised its full-year 2026 revenue guidance, but posted a net loss of $58.4 million after a $54.9 million non-cash impairment on APOKYN. The company also announced a definitive agreement to combine with Indivior Pharmaceuticals in an all-stock merger of equals, which would affect the ownership and business of Supernus shareholders.
Q2 2026 net loss of $58.4 million, or $1.01 per diluted share, versus net earnings of $22.5 million, or $0.40 per share, in Q2 2025
Full-year 2026 total revenue guidance raised to $860 million-$890 million from $840 million-$870 million; operating earnings guidance is now a loss of $20 million-$50 million, versus earnings of $0-$30 million previously
Adjusted operating earnings guidance raised to $150 million-$180 million from $140 million-$170 million
Merger exchange ratio is fixed; joint conference call with Indivior scheduled for August 3, 2026 at 8:30 a.m. EDT
Supernus and Indivior Pharmaceuticals agreed on August 1, 2026 to combine in an all-stock merger, with Supernus continuing as a wholly owned subsidiary of Indivior and the combined company renamed Supernus, Inc. Supernus shareholders would receive 1.5401 Indivior shares for each Supernus share and would own about 43.5% of the combined company, while Indivior holders would own about 56.5%. The merger is expected to close in the fourth quarter of 2026, subject to shareholder approvals, regulatory clearance and other conditions.
Each Supernus share converts into 1.5401 Indivior shares; the exchange ratio is fixed and will not adjust for changes in market prices.
Indivior holders would own about 56.5% and Supernus holders about 43.5% of the combined company, on a fully diluted basis.
Indivior will pay a special cash dividend of $1.0 billion before closing, financed partly by a $650 million Citibank term loan commitment.
Termination fees are $101 million if payable by Supernus and $174 million if payable by Indivior; expected closing is in the fourth quarter of 2026.
Supernus Pharmaceuticals said it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. The company will hold a conference call and webcast that day at 4:30 p.m. ET, led by CEO Jack Khattar and CFO Tim Dec. The announcement contains no financial results.
Second quarter 2026 results to be released after market close on August 4, 2026
Conference call and webcast set for August 4, 2026 at 4:30 p.m. ET
Replay to be available on the investor relations website for 60 days after the live call
Supernus reported first quarter 2026 total revenues of $207.7 million, up 39% from $149.8 million a year earlier, and a net loss of $2.3 million, or $0.04 per share, compared with a net loss of $11.8 million, or $0.21 per share, in the prior-year quarter. The company reiterated its full year 2026 financial guidance.
Total revenues were $207.7 million, up 39% year over year, including a $20.0 million licensing milestone from Shionogi.
Net loss narrowed to $2.3 million ($0.04 per share) from $11.8 million ($0.21 per share) a year earlier.
Full year 2026 guidance was reiterated, with total revenues of $840 million to $870 million and GAAP operating earnings of $0 to $30 million, as of February 24, 2026.
Supernus Pharmaceuticals announced it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026, with a conference call at 4:30 p.m. ET that day. The filing is a scheduling notice only and contains no financial results, so it gives shareholders no new information on performance.
First quarter 2026 results will be released after market close on Tuesday, May 5, 2026.
Conference call and webcast are scheduled for May 5, 2026 at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec.
The press release was dated April 22, 2026 and furnished as Exhibit 99.1; no financial figures are included.
On April 1, 2026, Supernus Pharmaceuticals entered into an asset purchase agreement with Navitor Pharmaceuticals to acquire rights to the compound NV-5138 or SPN-820, including intellectual property, inventory, regulatory materials and certain contract rights. The filing says the price consists of Supernus completing one Phase 2b study and making milestone payments of up to $350 million, and that Supernus can stop pursuing the compound if it judges the study unsuccessful. The filing reports no revenue or earnings figures, so the effect on shareholders depends on the study results and milestone achievement.
Agreement dated April 1, 2026, with Navitor Pharmaceuticals, Inc. and Navitor Pharmaceuticals, LLC
Purchase price: completion of one Phase 2b study plus milestone payments of up to $350 million
Supernus has no further obligation to pursue milestones or commercialization if it judges the post-study result unsuccessful
Agreement is filed as Exhibit 2.1, with some schedules and portions omitted
Supernus Pharmaceuticals approved annual base salary increases for five executive officers effective January 1, 2026, following its annual compensation review, and granted stock options, RSUs and PSUs. The changes are routine annual compensation actions, and the filing does not describe any change in officer roles.
CEO Jack A. Khattar's base salary rose from $1,036,000 to $1,067,100, with a 2025 bonus of $846,930 and options on 341,610 shares.
CFO Timothy C. Dec's base salary rose from $504,900 to $525,100, with a 2025 bonus of $233,894.
Option exercise price is $50.20 per share, the closing price on February 18, 2026, the date the grants were approved.
Option and RSU awards vest annually in equal increments over four years; PSU vesting depends on performance goals.
Supernus reported fourth-quarter and full-year 2025 results and issued 2026 guidance in a press release furnished as Exhibit 99.1. Revenue grew, but the company swung to a net loss, driven mainly by higher selling, general and administrative expenses, including about $72.9 million of Sage acquisition-related costs in 2025. The 2026 outlook projects total revenues of $840 million to $870 million and GAAP operating earnings of $0 to $30 million.
Q4 2025 total revenues were $211.6 million, up 21% from $174.2 million; full-year 2025 revenues were $719.0 million, up 9%.
Q4 2025 net loss was $4.1 million, or $0.07 per diluted share, versus net earnings of $15.3 million, or $0.27, a year earlier; full-year net loss was $38.6 million, or $0.68 per share.
2026 guidance: total revenues of $840 million to $870 million, GAAP operating earnings of $0 to $30 million, and adjusted operating earnings (non-GAAP) of $140 million to $170 million.
ONAPGO new patient initiation resumed in the first quarter of 2026; Q4 2025 ONAPGO net sales were $8.9 million.
Supernus Pharmaceuticals said it will report fourth quarter and full year 2025 financial and business results after the market closes on February 24, 2026, and will host a conference call and webcast that day at 4:30 p.m. ET. The filing is a scheduling notice only and contains no financial results, so it does not indicate how the company performed.
Results release scheduled for after market close on Tuesday, February 24, 2026
Conference call and webcast set for February 24, 2026 at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec
Filing contains no revenue, profit or guidance figures
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Supernus Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →